Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.
Achieving efficient in vivo delivery of siRNA to the appropriate target cell would be a major advance in the use of RNAi in gene function studies and as a therapeutic modality. Hepatocytes, the key parenchymal cells of the liver, are a particularly attractive target cell type for siRNA delivery given their central role in several infectious and metabolic disorders. We have developed a vehicle for the delivery of siRNA to hepatocytes both in vitro and in vivo, which we have named siRNA Dynamic PolyConjugates. Key features of the Dynamic PolyConjugate technology include a membrane-active polymer, the ability to reversibly mask the activity of this polymer until it reaches the acidic environment of endosomes, and the ability to target this modified polymer and its siRNA cargo specifically to hepatocytes in vivo after simple, low-pressure i.v. injection. Using this delivery technology, we demonstrate effective knockdown of two endogenous genes in mouse liver: apolipoprotein B (apoB) and peroxisome proliferator-activated receptor alpha (ppara). Knockdown of apoB resulted in clear phenotypic changes that included a significant reduction in serum cholesterol and increased fat accumulation in the liver, consistent with the known functions of apoB. Knockdown of ppara also resulted in a phenotype consistent with its known function, although with less penetrance than observed in apoB knockdown mice. Analyses of serum liver enzyme and cytokine levels in treated mice indicated that the siRNA Dynamic PolyConjugate was nontoxic and well tolerated.
Rozema
David B
DB
Mirus Bio Corporation, 505 South Rosa Road, Madison, WI 53719, USA. dave.rozema@mirusbio.com
Lewis
David L
DL
Wakefield
Darren H
DH
Wong
So C
SC
Klein
Jason J
JJ
Roesch
Paula L
PL
Bertin
Stephanie L
SL
Reppen
Tom W
TW
Chu
Qili
Q
Blokhin
Andrei V
AV
Hagstrom
James E
JE
Wolff
Jon A
JA
D000818:Animals; D001055:Apolipoproteins B / Q000037:antagonists & inhibitors* / Q000235:genetics; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D011992:Endosomes / Q000378:metabolism; D022781:Hepatocytes / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D010641:Phenotype; D011108:Polymers / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000032:analysis; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000378:metabolism
D001055:Apolipoproteins B; D011108:Polymers; D012333:RNA, Messenger; D034741:RNA, Small Interfering